Definium Therapeutics (DFTX) director gets 50,000 stock options grant

Rhea-AI Filing Summary

Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.

The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adsett Roger

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.24	01/29/2026		A		50,000		(1)	01/28/2036	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The shares underlying the option shall vest and become exercisable over a three-year period with 1/3 vesting on the first anniversary of the date of the grant and the remaining vesting in 24 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date.

	/s/ Mark Sullivan, Attorney-in-Fact for Roger Adsett	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Definium Therapeutics (DFTX) report for Roger Adsett?

Definium Therapeutics reported that director Roger Adsett received stock options for 50,000 common shares. The options were granted on January 29, 2026, as a compensation award and are exercisable at $17.24 per share, subject to a three-year vesting schedule.

How many stock options did Roger Adsett receive from Definium Therapeutics (DFTX)?

Roger Adsett received options covering 50,000 common shares of Definium Therapeutics. These options were granted as a single award and will vest in stages over three years, assuming he continues providing service to the company during the entire vesting period.

What is the exercise price of Roger Adsett’s Definium Therapeutics (DFTX) stock options?

The exercise price of Roger Adsett’s stock options is $17.24 per share. This means he can buy up to 50,000 Definium Therapeutics common shares at $17.24, once the options have vested according to the specified three-year vesting schedule.

How do Roger Adsett’s Definium Therapeutics (DFTX) options vest over time?

The options vest over three years. One-third of the 50,000 options vests on the first anniversary of the grant date, and the remaining two-thirds vest in 24 equal monthly installments, if Roger Adsett continues serving the company throughout this period.

Are Roger Adsett’s Definium Therapeutics (DFTX) stock options held directly or indirectly?

Roger Adsett’s 50,000 Definium Therapeutics stock options are reported as held directly. The filing does not attribute them to any trust, partnership, or other entity, and no footnote disclaims his beneficial ownership or voting and investment authority.

What type of security did Roger Adsett receive from Definium Therapeutics (DFTX)?

Roger Adsett received a derivative security classified as a stock option, described as a right to buy common shares. The award covers 50,000 underlying common shares and was granted at an exercise price of $17.24 per share on January 29, 2026.